Adalimumab for treating moderate to severe hidradenitis suppurativa

Adalimumab is recommended, within its marketing authorisation, as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy. The drug is recommended only if the company provides it at the price agreed in the patient access scheme.

Assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear evidence of response, defined as:

• a reduction of 25% or more in the total abscess and inflammatory nodule count and

• no increase in abscesses and draining fistulas.